艾美健康科技有限公司 2025年季度报告

FORM10-Q Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☒No☐ Aimei Health Technology Co., LtdForm 10-QFor the Quarterly Period Ended March 31, 2025ContentsPart IFinancial Information1Item 1Financial Statements1Unaudited Balance Sheets as of March 31, 2025 and December 31, 20241Unaudited Statements of Operations for the three months ended March 31, 2025 and 20242Unaudited Statements of Changes in Shareholders’ Deficit for the three months ended March 31, 2025 and 20243Unaudited Statements of Cash Flows for the three months ended March 31, 2025 and 20244Notes to Unaudited Financial Statements5Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3Quantitative and Qualitative Disclosures about Market Risk19Item 4Controls and Procedures19Part IIOther Information20Item 1Legal Proceedings20Item 1ARisk Factors20Item 2Unregistered Sales of Equity Securities and Use of Proceeds20Item 3Defaults Upon Senior Securities20Item 4Mine Safety Disclosures21Item 5Other Information21Item 6Exhibits21Signature22i AIMEI HEALTH TECHNOLOGY CO., LTDPART I - FINANCIAL INFORMATION AIMEI HEALTH TECHNOLOGY CO., LTDNOTES TO UNAUDITED FINANCIAL STATEMENTS NOTE 1 -ORGANIZATION AND BUSINESS BACKGROUND Aimei Health Technology Co., Ltd. (the “Company”) is a blank check company incorporated in the Cayman Islands onApril 27, 2023.TheCompany was formed for the purpose of entering into a merger,share exchange,asset acquisition,share purchase,recapitalization, reorganization or similar business combination with one or more businesses or entities. Although there is norestriction or limitation on what industry its target operates in, it is the Company’s intention to pursue prospective targets that arefocused on healthcare innovation. The Company anticipates targeting what are traditionally known as “small cap” companies As of March 31, 2025, the Company had not yet commenced any operations. All activities through March 31, 2025 related to theCompany’s formation and the Initial Public Offering (as defined below). Since the Initial Public Offering, the Company’s activity hasbeen limited to the costs in pursuit of the consummation of an initial business combination. The Company will not generate anyoperating revenue until after the completion of its initial business combination, at the earliest. The Company will generate non- The Company’s sponsor is Aimei Investment Ltd, a Cayman Islands exempted company (the “Sponsor”). The registration statementfor the Company’s Initial Public Offering was declared effective on November 30, 2023. On December 6, 2023, the Companyconsummated its Initial Public Offering of6,900,000units (the “Units” and, with respect to the ordinary shares included in the Unitsbeing offered, the “Public Shares”), at $10.00per Unit, which includes full exercise of the underwriters’ over-allotment optionof900,000 Units, generating gross proceeds of $69,000,000(the “Initial Public Offering”), and incurring offering costs of$2,070,665and $690,000for deferred underwriting commissions (see Note 7). The Company granted the underwriters a 45-day option Simultaneously with the consummation of the closing of the Offering, the Company consummated the private placement of anaggregate of332,000units (the “Private Units”) to the Sponsor at a price of $10.00per Unit, generating total gross proceeds of Following the closing of the Initial Public Offering on December 6, 2023, an amount of $69,690,000($10.10per Unit) from the netproceeds of the sale of the Units in the Initial Public Offering and a portion of the proceeds from the sale of the Private Units wasplaced in a trust account (the “Trust Account”), located in the United States and held as cash items or may be invested only in U.S.government treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain